Chip Diagnostics is developing the microDroplet Fluorescence Detector platform that can enable digital assays without bulky lab equipment
Formed in 2016, Chip Diagonostics is a diagnostic device company based on David Issadore's groundbreaking research combining microelectronics, microfluidics, and nanomaterials that will enable digital assays with mobile devices.
Digital assays have enormous untapped potential for disease diagnostics, environmental surveillance, and biosafety monitoring, but are currently confined to laboratory settings due to the instrumentation necessary to generate, control, and measure tens of millions of independent droplets. Chip Diagnostics is developing the microDroplet Fluorescence Detector (µDFD), a mobile compatible device enabling digital assays by using an original microfluidic droplet production process, a high bandwidth of electronics, new sensing technology, and ubiquitously available cloud computing.
Chip Diagnostics' microDroplet Fluorescence Detector (µDFD) is a hybrid microelectronic/microfluidic chip that 'unlocks' droplet based assays for mobile use, recording ultra-sensitive molecular measurements by performing millions of parallel experiments in picoliter droplets.
Current microfludic cell sensors are too slow by 100x to be meaningful in detecting the billions of cells in a sample of blood. Our µDFD platform increases microfluidic droplet production rate by 104x by incorporating thousands of droplet generators onto a single chip and by using on-chip delay lines to perform droplet PCR on >107 droplets/minute.
Our µDFD platform generates and detects the fluorescence of millions of droplets per second (1000x faster than conventional approaches) only using a cell phone camera. Our key innovation is amplitude modulation of the signal from fluorescent droplets using distinct micro-patterning of the droplet signal, akin to the carrier frequency modulation used in cellular networks.
The detection of diseases or pathogen contamination is inherently challenging due to the complex, heterogeneous nature of disease and contaminations. To solve this challenge, our µDFD platform allows measurement of multiple molecular biomarkers for little marginal increase in cost with a sensitivity that matches gold standard technologies.